ES2552587R1 - Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes - Google Patents

Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes Download PDF

Info

Publication number
ES2552587R1
ES2552587R1 ES201430796A ES201430796A ES2552587R1 ES 2552587 R1 ES2552587 R1 ES 2552587R1 ES 201430796 A ES201430796 A ES 201430796A ES 201430796 A ES201430796 A ES 201430796A ES 2552587 R1 ES2552587 R1 ES 2552587R1
Authority
ES
Spain
Prior art keywords
socs1
peptide derived
diabetes
chronic complications
complications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201430796A
Other languages
English (en)
Other versions
ES2552587B1 (es
ES2552587A2 (es
Inventor
Jesús EGIDO DE LOS RÍOS
Carmen GÓMEZ GUERRERO
Rafael Simó Canonge
Cristina Hernández Pascual
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion Instituto De Investigacion Sanitaria Fun
Original Assignee
Universidad Autonoma de Madrid
Fundacio Hospital Universitari Vall dHebron Institut de Recerca FIR VHIR
Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES201430796A priority Critical patent/ES2552587B1/es
Application filed by Universidad Autonoma de Madrid, Fundacio Hospital Universitari Vall dHebron Institut de Recerca FIR VHIR, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz filed Critical Universidad Autonoma de Madrid
Priority to EP15738128.6A priority patent/EP3178485B1/en
Priority to HUE15738128A priority patent/HUE041836T2/hu
Priority to TR2019/03509T priority patent/TR201903509T4/tr
Priority to MX2016015514A priority patent/MX369378B/es
Priority to PT15738128T priority patent/PT3178485T/pt
Priority to JP2017514978A priority patent/JP6681387B2/ja
Priority to CN201580040669.6A priority patent/CN107074922A/zh
Priority to ES15738128T priority patent/ES2715412T3/es
Priority to US15/314,395 priority patent/US10532082B2/en
Priority to CA2950348A priority patent/CA2950348A1/en
Priority to PCT/ES2015/070415 priority patent/WO2015181427A1/es
Priority to BR112016027936A priority patent/BR112016027936A2/pt
Priority to PL15738128T priority patent/PL3178485T3/pl
Publication of ES2552587A2 publication Critical patent/ES2552587A2/es
Publication of ES2552587R1 publication Critical patent/ES2552587R1/es
Application granted granted Critical
Publication of ES2552587B1 publication Critical patent/ES2552587B1/es
Priority to US16/689,924 priority patent/US20200138903A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Péptido derivado de SOCS1 para su uso en complicaciones crónicas de la diabetes, especialmente complicaciones oculares, renales, nerviosas y vasculares, así como composiciones que lo contienen y polinucleótidos aislados que lo codifican.
ES201430796A 2014-05-28 2014-05-28 Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes Expired - Fee Related ES2552587B1 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
ES201430796A ES2552587B1 (es) 2014-05-28 2014-05-28 Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes
CA2950348A CA2950348A1 (en) 2014-05-28 2015-05-27 Socs1-derived peptide for use in chronic complications of diabetes
TR2019/03509T TR201903509T4 (tr) 2014-05-28 2015-05-27 Diyabet ile ilişkili kronik komplikasyonlarda kullanıma yönelik socs1-türevli peptit.
MX2016015514A MX369378B (es) 2014-05-28 2015-05-27 Peptido derivado de socs1 para su uso en complicaciones cronicas de la diabetes.
PT15738128T PT3178485T (pt) 2014-05-28 2015-05-27 Péptido derivado de socs1 para utilização em complicações crónicas relacionadas com a diabetes
JP2017514978A JP6681387B2 (ja) 2014-05-28 2015-05-27 糖尿病の慢性合併症において使用するためのｓｏｃｓ１由来ペプチド
CN201580040669.6A CN107074922A (zh) 2014-05-28 2015-05-27 用于糖尿病慢性并发症的socs1衍生肽
ES15738128T ES2715412T3 (es) 2014-05-28 2015-05-27 Péptido derivado de SOCS1 para su uso en complicaciones crónicas de la diabetes
EP15738128.6A EP3178485B1 (en) 2014-05-28 2015-05-27 Socs1-derived peptide for use in chronic complications relating to diabetes
HUE15738128A HUE041836T2 (hu) 2014-05-28 2015-05-27 SOCS1-eredetû peptidek, cukorbetegség krónikus szövõdményeiben történõ alkalmazásra
PCT/ES2015/070415 WO2015181427A1 (es) 2014-05-28 2015-05-27 Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes
BR112016027936A BR112016027936A2 (pt) 2014-05-28 2015-05-27 peptídeo derivado de socs1 para o seu uso em complicações crônicas da diabetes
PL15738128T PL3178485T3 (pl) 2014-05-28 2015-05-27 Peptyd pochodzący z socs1 do zastosowania w przewlekłych powikłaniach powiązanych z cukrzycą
US15/314,395 US10532082B2 (en) 2014-05-28 2015-05-27 SOCS1-derived peptide for use in chronic complications of diabetes
US16/689,924 US20200138903A1 (en) 2014-05-28 2019-11-20 Socs1-derived peptide for use in chronic complications of diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430796A ES2552587B1 (es) 2014-05-28 2014-05-28 Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes

Publications (3)

Publication Number Publication Date
ES2552587A2 ES2552587A2 (es) 2015-11-30
ES2552587R1 true ES2552587R1 (es) 2016-02-10
ES2552587B1 ES2552587B1 (es) 2017-01-18

Family

ID=53546661

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201430796A Expired - Fee Related ES2552587B1 (es) 2014-05-28 2014-05-28 Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes
ES15738128T Active ES2715412T3 (es) 2014-05-28 2015-05-27 Péptido derivado de SOCS1 para su uso en complicaciones crónicas de la diabetes

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15738128T Active ES2715412T3 (es) 2014-05-28 2015-05-27 Péptido derivado de SOCS1 para su uso en complicaciones crónicas de la diabetes

Country Status (13)

Country Link
US (2) US10532082B2 (es)
EP (1) EP3178485B1 (es)
JP (1) JP6681387B2 (es)
CN (1) CN107074922A (es)
BR (1) BR112016027936A2 (es)
CA (1) CA2950348A1 (es)
ES (2) ES2552587B1 (es)
HU (1) HUE041836T2 (es)
MX (1) MX369378B (es)
PL (1) PL3178485T3 (es)
PT (1) PT3178485T (es)
TR (1) TR201903509T4 (es)
WO (1) WO2015181427A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552587B1 (es) 2014-05-28 2017-01-18 Fundació Hospital Universitari Vall D'hebron-Institut De Recerca Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes
CN105315377A (zh) * 2015-12-07 2016-02-10 华东理工大学 带有穿膜肽的tcs融合蛋白、质粒及制备方法与应用
MA43801A (fr) * 2016-02-23 2018-11-28 Takeda Pharmaceuticals Co Inhibiteurs des interactions des récepteurs de bêta-arrestine-neurokinine 1 pour le traitement de la douleur
CN106349347B (zh) * 2016-10-25 2019-09-13 南通大学 一种小分子多肽、及其编码基因和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175971A1 (en) * 2001-12-28 2003-09-18 Geoffrey Lindeman Differentiation and/or proliferation modulating agents and uses therefor
WO2005086800A2 (en) 2004-03-04 2005-09-22 Vanderbilt University Cell-penetrating socs polypeptides that inhibit cytokine-induced signaling
CA2574572A1 (en) * 2004-07-19 2006-10-26 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
US20090030179A1 (en) 2005-02-15 2009-01-29 Toagosei Co., Ltd Antimicrobial peptide and use thereof
WO2007010989A1 (ja) 2005-07-20 2007-01-25 Toagosei Co., Ltd. 神経分化誘導ペプチド及びその利用
WO2010151495A2 (en) 2009-06-26 2010-12-29 University Of Florida Research Foundation Inc. Materials and methods for treating and preventing viral infections
WO2011113048A2 (en) * 2010-03-12 2011-09-15 Vanderbilt University Modulation of cytokine signaling
WO2013020372A1 (zh) * 2011-08-09 2013-02-14 中国科学院上海生命科学研究院 防治胰岛素抵抗和糖尿病的方法和试剂
CN103173446A (zh) * 2011-12-26 2013-06-26 吕成伟 一种靶向干扰socs1基因的重组腺相关病毒载体的构建方法与应用
ES2552587B1 (es) 2014-05-28 2017-01-18 Fundació Hospital Universitari Vall D'hebron-Institut De Recerca Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHENG-RONG YU et al. Suppressor of Cytokine Signaling-1 (SOCS1) Inhibits Lymphocyte Recruitment into the Retina and Protects SOCS1 Transgenic Rats and Mice from Ocular Inflammation.Investigative Opthalmology & Visual Science, 20110831 C.V. Mosby Co 31/08/2011 VOL: 52 No: 9 Pags: 6978 ISSN 1552-5783 Doi: doi:10.1167/iovs.11-7688 *
LINDSEY D JAGER et al. The kinase inhibitory region of SOCS-1 is sufficient to inhibit T-helper 17 and other immune functions in experimental allergic encephalomyelitis.JOURNAL OF NEUROIMMUNOLOGY, 20101019 ELSEVIER SCIENCE PUBLISHERS BV, NL 19/10/2010 VOL: 232 No: 1 Pags: 108 - 118 ISSN 0165-5728 Doi: doi:10.1016/j.jneuroim.2010.10.018 Racke Michael K; Comabella Manuel *
MATTERN RALPH-HEIKO et al. Effect of RGD peptides in in vivo model for diabetic retinopathy.Peptide Revolution: Genomics, Proteomics & Therapeutics (18th American Peptide Symposium; BOSTON, MA, USA; July 19 -23, 2003), 20030719; 20030719 - 20030723 xx, xx 19/07/2003 VOL: Pags: 709 - 710 ISBN 978-0-9715560-1-0 ; ISBN 0-9715560-1-6 *
ORTIZ-MUNOZ G et al. Suppressors of Cytokine Signaling Abrogate Diabetic Nephropathy.Journal of the American Society of Nephrology, 20100501 01/05/2010 VOL: 21 No: 5 Pags: 763 - 772 ISSN 1046-6673 Doi: doi:10.1681/ASN.2009060625 *

Also Published As

Publication number Publication date
JP6681387B2 (ja) 2020-04-15
EP3178485B1 (en) 2018-12-12
US10532082B2 (en) 2020-01-14
ES2552587B1 (es) 2017-01-18
BR112016027936A2 (pt) 2017-10-24
PT3178485T (pt) 2019-03-22
PL3178485T3 (pl) 2019-07-31
MX2016015514A (es) 2017-05-04
CA2950348A1 (en) 2015-12-03
TR201903509T4 (tr) 2019-04-22
EP3178485A1 (en) 2017-06-14
MX369378B (es) 2019-11-07
US20170209536A1 (en) 2017-07-27
WO2015181427A1 (es) 2015-12-03
CN107074922A (zh) 2017-08-18
US20200138903A1 (en) 2020-05-07
ES2715412T3 (es) 2019-06-04
ES2552587A2 (es) 2015-11-30
HUE041836T2 (hu) 2019-05-28
JP2017524727A (ja) 2017-08-31

Similar Documents

Publication Publication Date Title
PH12016501763A1 (en) Multispecific antibodies
BR112016018521A2 (pt) composição, e, kit.
LT3426226T (lt) Oftalmologinė kompozicija
ES2897914T8 (es) Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos
EP3556343A4 (en) COMPOSITION OF OIL-IN-WATER TYPE
ES2552587R1 (es) Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes
GB201610400D0 (en) Vascular calcification
EP3299025A4 (en) COMPOSITION WITH QUISQUALIS INDICA
HK1254371A1 (zh) 粘彈性組合物
MX365440B (es) Compuestos organolepticos novedosos.
CL2018001010A1 (es) Componentes y métodos para separar líquidos inmiscibles.
ZA201706254B (en) Oil blends, processes for the preparation thereof and their use in formulas
PL3456454T3 (pl) Przeciągacz
IT201600069848A1 (it) Friggitrice.
DK3096839T3 (da) Duftende sammensætninger til kroppen
GB2534899B (en) Double ended vascular filter.
GB201513543D0 (en) Compositions for use in the treatment of diabetes
EP3130229A4 (en) Mung bean protein composition
Dickins The old bamboo-hewer's story (Taketori no okina no monogatari)
Yesenin Kačalovljevom psu
Dimitrijovska-Radevska Davnine
UY4559S (es) Mesas de juegos
ES1146383Y (es) Envase porrón de un solo uso
ES1159038Y (es) Nueva pieza de ajedrez.
TH1601000953A (th) พอลิเพพไทด์ที่เสถียรที่จับเกาะกับคอมพลีเมนต์ c5 ของมนุษย์

Legal Events

Date Code Title Description
PC2A Transfer of patent

Owner name: FUNDACION INSTITUTO DE INVESTIGACION SANITARIA FUN

Effective date: 20161221

FG2A Definitive protection

Ref document number: 2552587

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20170118

FD2A Announcement of lapse in spain

Effective date: 20211004